The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Originally a blockbuster drug, yielding billions in income, its intellectual property lapse created a flood of knock-off medications, significantly eroding its dominance. While certain pharmaceutical companies may attempt to capitalize on related trea… Read More